C12N 2760/16233
Use of viral protein as therapeutic agent other than vaccine
Official title: Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N2760/16233 (Use of viral protein as therapeutic agent other than vaccine) appears on 4 US grants and 9 published applications in this corpus.
Search patents in C12N- Granted patents
- 4
- Published applications
- 9
- Assignees
- 7
- Inventors
- 14
- Latest grant
- 1 Nov 2022
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2006 | 0 | 1 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 0 | 0 |
| 2010 | 0 | 1 |
| 2011 | 1 | 0 |
| 2012 | 1 | 1 |
| 2013 | 0 | 1 |
| 2014 | 0 | 0 |
| 2015 | 0 | 1 |
| 2016 | 1 | 1 |
| 2017 | 0 | 0 |
| 2018 | 0 | 0 |
| 2019 | 0 | 0 |
| 2020 | 0 | 0 |
| 2021 | 0 | 0 |
| 2022 | 1 | 0 |
| 2023 | 0 | 1 |
| 2024 | 0 | 1 |
| 2025 | 0 | 1 |
By publication year.
Recent patents
- Use of immune suppressive domains as medicaments1 Nov 2022US 11,484,567 B2Aarhus Universitet
- Polyanionic polymer adjuvants for Haemophilus influenzae B saccharide vaccines14 Jun 2016US 9,364,533 B2Glaxosmithkline Biologicals SA
- Polyanionic polymer adjuvants for Haemophilus influenzae B saccharide vaccines20 Mar 2012US 8,137,681 B2Glaxosmithkline Biologicals SA
- Polyanionic polymer adjuvants for haemophilus influenzae B saccharide vaccines30 Aug 2011US 8,007,818 B2GlaxoSmithKline Biologicals, S.R.
- Intranasal vaccine composition and method for boosting using the same2 Jan 2025US 2025/0000972 A1Advagene Biopharma Co., Ltd.
- Viral delivery of a sialidase to treat cancer12 Sep 2024US 2024/0299582 A1UniversitäT Basel
- Use of Immune Suppressive Domains as Medicaments11 May 2023US 2023/0141663 A1Aarhus Universitet
- Use of Immune Suppressive Domains as Medicaments23 Jun 2016US 2016/0175387 A1Aarhus Universitet
- Polyanionic polymer adjuvants for haemophilus influenzae b saccharide vaccines5 Feb 2015US 2015/0037368 A1Glaxosmithkline Biologicals SA
Most cited
By later US patents